BioPharma Credit (BPCR) Competitors GBX 0.89 +0.01 (+1.14%) As of 11:53 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsDividendHeadlinesInsider TradesBuy This Stock BPCR vs. PCT, ATST, ABDN, 3IN, PHLL, RCP, JGGI, BUR, EMG, and HICLShould you be buying BioPharma Credit stock or one of its competitors? The main competitors of BioPharma Credit include Polar Capital Technology Trust (PCT), Alliance Trust (ATST), abrdn (ABDN), 3i Infrastructure (3IN), Petershill Partners (PHLL), RIT Capital Partners (RCP), JPMorgan Global Growth & Income (JGGI), Burford Capital (BUR), Man Group (EMG), and HICL Infrastructure (HICL). These companies are all part of the "asset management" industry. BioPharma Credit vs. Its Competitors Polar Capital Technology Trust Alliance Trust abrdn 3i Infrastructure Petershill Partners RIT Capital Partners JPMorgan Global Growth & Income Burford Capital Man Group HICL Infrastructure BioPharma Credit (LON:BPCR) and Polar Capital Technology Trust (LON:PCT) are both financial services companies, but which is the better stock? We will contrast the two companies based on the strength of their community ranking, dividends, earnings, valuation, institutional ownership, risk, analyst recommendations, media sentiment and profitability. Which has better earnings & valuation, BPCR or PCT? BioPharma Credit has higher revenue and earnings than Polar Capital Technology Trust. Polar Capital Technology Trust is trading at a lower price-to-earnings ratio than BioPharma Credit, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioPharma Credit£12.99B0.08£10.42B£0.0910.09Polar Capital Technology Trust£1.24B3.25£1.20B£101.863.37 Is BPCR or PCT more profitable? Polar Capital Technology Trust has a net margin of 96.56% compared to BioPharma Credit's net margin of 80.20%. Polar Capital Technology Trust's return on equity of 30.54% beat BioPharma Credit's return on equity.Company Net Margins Return on Equity Return on Assets BioPharma Credit80.20% 8.51% 4.98% Polar Capital Technology Trust 96.56%30.54%20.70% Does the media refer more to BPCR or PCT? In the previous week, BioPharma Credit's average media sentiment score of 0.00 equaled Polar Capital Technology Trust'saverage media sentiment score. Company Overall Sentiment BioPharma Credit Neutral Polar Capital Technology Trust Neutral Which has more volatility & risk, BPCR or PCT? BioPharma Credit has a beta of 0.22, meaning that its share price is 78% less volatile than the S&P 500. Comparatively, Polar Capital Technology Trust has a beta of 0.49, meaning that its share price is 51% less volatile than the S&P 500. Does the MarketBeat Community favor BPCR or PCT? BioPharma Credit received 1 more outperform votes than Polar Capital Technology Trust when rated by MarketBeat users. Likewise, 64.62% of users gave BioPharma Credit an outperform vote while only 64.34% of users gave Polar Capital Technology Trust an outperform vote. CompanyUnderperformOutperformBioPharma CreditOutperform Votes8464.62% Underperform Votes4635.38% Polar Capital Technology TrustOutperform Votes8364.34% Underperform Votes4635.66% Do institutionals & insiders have more ownership in BPCR or PCT? 41.5% of BioPharma Credit shares are owned by institutional investors. Comparatively, 43.2% of Polar Capital Technology Trust shares are owned by institutional investors. 6.2% of BioPharma Credit shares are owned by insiders. Comparatively, 1.2% of Polar Capital Technology Trust shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. SummaryPolar Capital Technology Trust beats BioPharma Credit on 7 of the 13 factors compared between the two stocks. Get BioPharma Credit News Delivered to You Automatically Sign up to receive the latest news and ratings for BPCR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BPCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BPCR vs. The Competition Export to ExcelMetricBioPharma CreditAsset Management IndustryFinancial SectorLON ExchangeMarket Cap£1.05B£1.22B£5.70B£2.93BDividend Yield13.43%4.34%4.13%4.90%P/E Ratio10.0921.6612.77129.28Price / Sales0.082,364.211,690.21243,462.16Price / Cash1.1960.8149.9228.09Price / Book0.011.182.854.60Net Income£10.42B£264.77M£1.23B£5.92B7 Day Performance1.37%0.97%1.18%7.20%1 Month PerformanceN/A18.83%10.61%17.00%1 Year Performance4.96%5.48%14.73%83.16% BioPharma Credit Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BPCRBioPharma CreditN/AGBX 0.89+1.1%N/A+3.8%£1.05B£12.99B10.09N/APCTPolar Capital Technology TrustN/AGBX 337.50+1.2%N/A-89.1%£3.98B£1.24B3.31120Positive NewsATSTAlliance TrustN/AN/AN/AN/A£3.58B£652.76M600.003ABDNabrdn0.7197 of 5 starsGBX 174.64-2.7%GBX 163.50-6.4%+31.3%£3.13B£1.49B9.934,719News Coverage3IN3i InfrastructureN/AGBX 335+0.3%N/A+5.9%£3.09B£374M881.58N/ANews CoveragePHLLPetershill Partners2.6548 of 5 starsGBX 215+0.9%GBX 240+11.6%+2.6%£2.92B£706.00M8.72N/AGap DownRCPRIT Capital PartnersN/AGBX 1,922+0.5%N/A+6.4%£2.77B£103.46M16.6162News CoveragePositive NewsJGGIJPMorgan Global Growth & IncomeN/AGBX 534+0.8%N/A-1.3%£2.75B£660.56M4.40N/ANews CoveragePositive NewsBURBurford Capital2.7335 of 5 starsGBX 937-1.3%GBX 1,600+70.8%-10.3%£2.58B£299.55M16.76140EMGMan Group2.5815 of 5 starsGBX 174.60-0.7%GBX 278+59.2%-30.9%£2.52B£1.69B8.241,790HICLHICL InfrastructureN/AGBX 120.40+0.8%N/A+2.5%£2.40B£105.30M23.62N/A Related Companies and Tools Related Companies Polar Capital Technology Trust Alternatives Alliance Trust Alternatives abrdn Alternatives 3i Infrastructure Alternatives Petershill Partners Alternatives RIT Capital Partners Alternatives JPMorgan Global Growth & Income Alternatives Burford Capital Alternatives Man Group Alternatives HICL Infrastructure Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (LON:BPCR) was last updated on 6/11/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioPharma Credit Please log in to your account or sign up in order to add this asset to your watchlist. Share BioPharma Credit With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
